Thorpe KE, Joski P, Johnston KJ. Health Aff (Millwood) 2018 Apr;37(4):662-669. doi: 10.1377/hlthaff.2017.1153. Epub 2018 Mar 21. Abstract Antibiotic-resistant infections are a global health care concern. The Centers for Disease Control and Prevention estimates that 23,000 Americans with these infections die each year. Rising infection rates add to the costs of [...]
Adiarin® is recommended for the protection of gut lining in diarrhea in children and adults. It is the first Noventure product in Russia. Tasectan® in Europe is a class III medical device and complies with the Essential Requirements of Directive 93/42/EEC and subsequent amendments. (CE 0373, Novinthetical Pharma SA). In [...]
We are pleased to announce that we are expanding the international coverage of our products thanks to the recent signature of agreements with both new and loyal partners. These new partnerships further enable us to spread our global footprint. Soon you will be able to find our products in the [...]
Barcelona, Spain, February 22, 2018 – Noventure and Laboratorios Salvat, S.A. (Salvat), announce today that they have entered into an agreement in which Salvat will distribute Noventure’s nasal mucoprotection product in Spain and Portugal. The product contains a mucomimetic agent that forms a protective barrier over the nasal epithelial mucosa. This [...]
Szajewska H, Kołodziej M, Łukasik J. Drug development and acute gastrointestinal infections. Expert Opin Investig Drugs. 2017 Dec 26:1-6 Expert Opin Investig Drugs. 2017 Dec 26:1-6. NO ABSTRACT AVAILABLE Mucoprotectans chapter: 4. Mucosal protective agents Clarifying the role of intestinal mucus in reducing inflammation and infection has led to the [...]
We are pleased to announce the launch in France of UTIPRO® PLUS, our product for uncomplicated Urinary Tract Infections. The product is commercialized over the French territory under the umbrella brand Cysticare / Utipro plus and is distributed by Vemedia, our partner for the product in the Netherlands as well. [...]
We are pleased to announce the launch in Israel of UTIPRO® PLUS, our product for uncomplicated Urinary Tract Infections. The product is distributed by our long term partner Lapidot. Utipro® Plus is a medical device intended for the control and prevention of urinary tract infections produced by pathogens such as [...]
We are pleased to announce the launch of Tasectan® Duo in Austria by our partner company Montavit. This will be Duo´s second market, after the successful introduction in Italy by Angelini. Tasectan® Duo is the first combination of gelatin tannate and inactivated bacteria, and can be used to re-establish [...]
Eutamene, Beaufrand Harkat C, Theodorou V. EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2018 ABSTRACT Introduction: The intestinal barrier controls the absorption of nutrients and water whilst helping to prevent the entry of toxins and pathogenic micro-organisms from the lumen into the tissues. Deficiencies in the barrier are associated with various [...]
Servi B, Ranzini F. Protective efficacy of antidiarrheal agents in a permeability model of Escherichia coli-infected CacoGoblet® cells. Future Microbiol. 2017 Oct 25. Future Microbiol. 2017 Oct 25. Abstract: Aim: To compare the protective efficacy of gelatine tannate/probiotic with other antidiarrheal agents in Escherichia coli-inoculated CacoGoblet® cells. Methods: Four test compounds [...]